Peripheral injection of human umbilical cord blood stimulates neurogenesis in the aged rat brain by unknown
BioMed CentralBMC Neuroscience
ssOpen AcceResearch article
Peripheral injection of human umbilical cord blood stimulates 
neurogenesis in the aged rat brain
Adam D Bachstetter1,2, Mibel M Pabon1,2, Michael J Cole2, 
Charles E Hudson3, Paul R Sanberg1,2,4, Alison E Willing1,2, 
Paula C Bickford1,2,3 and Carmelina Gemma*1,2,3
Address: 1Department of Molecular Pharmacology and Physiology, University of South Florida, College of Medicine, Tampa, FL 33612, USA, 
2Department of Neurosurgery, Center of Excellence for Aging and Brain Repair, University of South Florida, College of Medicine, Tampa, FL 33612, 
USA, 3James A. Haley Veterans Administration Hospital, Tampa, FL 33612, USA and 4Saneron CCEL Therapeutics Inc., Temple Terrace, FL 33617, 
USA
Email: Adam D Bachstetter - abachste@health.usf.edu; Mibel M Pabon - mpabon@health.usf.edu; Michael J Cole - mcole@health.usf.edu; 
Charles E Hudson - chudson1@health.usf.edu; Paul R Sanberg - psanberg@health.usf.edu; Alison E Willing - awilling@health.usf.edu; 
Paula C Bickford - pbickfor@health.usf.edu; Carmelina Gemma* - cgemma@health.usf.edu
* Corresponding author    
Abstract
Background: Neurogenesis continues to occur throughout life but dramatically decreases with
increasing age. This decrease is mostly related to a decline in proliferative activity as a result of an
impoverishment of the microenvironment of the aged brain, including a reduction in trophic factors
and increased inflammation.
Results: We determined that human umbilical cord blood mononuclear cells (UCBMC) given
peripherally, by an intravenous injection, could rejuvenate the proliferative activity of the aged
neural stem/progenitor cells. This increase in proliferation lasted for at least 15 days after the
delivery of the UCBMC. Along with the increase in proliferation following UCBMC treatment, an
increase in neurogenesis was also found in the aged animals. The increase in neurogenesis as a
result of UCBMC treatment seemed to be due to a decrease in inflammation, as a decrease in the
number of activated microglia was found and this decrease correlated with the increase in
neurogenesis.
Conclusion: The results demonstrate that a single intravenous injection of UCBMC in aged rats
can significantly improve the microenvironment of the aged hippocampus and rejuvenate the aged
neural stem/progenitor cells. Our results raise the possibility of a peripherally administered cell
therapy as an effective approach to improve the microenvironment of the aged brain.
Background
Aging is accompanied by a process of cellular senescence
that occurs throughout the body, resulting in a decrease in
the regenerative potential of the stem cell pools [1]. In the
brain there are two stem cell pools, one residing in the
subventricular zone (SVZ), and the other in the subgranu-
lar zone (SGZ) of the dentate gyrus of the hippocampus.
As in other stem cell pools such as the hemapoietic pool
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cle, the stem cells in the brain lose there capacity to gener-
ate new cells with age [2-4]. In the brain it appears that the
decrease in neurogenesis is a result of a decrease in prolif-
eration of the stem cells and not due to a loss of the cells
[5]. In the muscle it has been shown that the stem cells can
be rejuvenated by exposure of the cells to the systemic
environment of a young animal through parabiosis [6].
Even though it has been known since the 1960s that a cel-
lular senescence occurs with age [7], it is less clear if this
cellular senescence leads to an aging phenotype, particu-
larly to the age related cognitive decline.
However, it is clear that the process of cellular senescence
that occurs with age is an important mechanism to protect
against cancer. There are a number of tumor-supressor
genes, including p53 and p16ink4A, which respond to cel-
lular stressors to induce senescence [8]. It has recently
been shown that knocking out p16ink4A can restore the
proliferative potential of the aged neural stem cells [9],
but the animals have decreased longevity due to tumor
formation [10]. This demonstrates the important balance
that oncogenes play in protecting organisms from cancer,
but with the negative consequence of inducing an aging
state of cellular senescence. An effective target to lessen the
amount of senescence might be the cellular stressors that
accumulate with age which include telomere shorting [1],
oxidative stress [11-13], inflammation [14], increased cor-
ticosteroid levels [15], and a decrease in a number of
trophic factors including brain-derived neurotrophic fac-
tor (BDNF), vascular endothelial growth factor (VEGF),
Insulin-like Growth Factor-1 (IGF-1) and fibroblast
growth factor 2 (FGF-2) [16,17].
A potent cellular stressor that is increased with age is
inflammation. Recently, our laboratory has shown that
reducing neuroinflammation in aged rats by blocking the
conversion of pro-IL-1β to IL-1β through inhibition of the
converting enzyme caspase-1 rescued some of the age-
related decrease in neurogenesis [18] and resulted in an
improvement in cognitive function [19]. We believed that
human umbilical cord blood mononuclear cells
(UCBMC) may have a similar potential to restore some of
the loss in capacity of the neural stem/progenitor cells
ability to proliferate and differentiate into neurons.
In an animal model of stroke, UCBMC administered
intravenously have reduced infarct volume and improved
functional recovery on behavioral measures [20]. The
effects of UCBMC have been attributed to changes in the
microenvironment of the brain, through the release of
trophic factors or by reducing inflammation, and not by a
direct replacement of cells [21-23]. UCBMC contains a
number of cell types including B-Cells and T-Cells, as well
as, mesenchymal and endothelial progenitor cells.
UCBMC is also a rich source of CD34+ hematopoietic
stem cells [24-26]. It was recently demonstrated that a sys-
temic injection of UCBMC cells could suppress inflamma-
tion in the brain following stroke. Moreover, the effects of
UCBMC cells seemed to shift the cytokine expression
from a Th1 response to a Th2 response [20,23,27]. In
addition to the immune modulatory effects, UCBMC cells
also produce a number of trophic factors including, but
not limited to, VEGF, nerve growth factor, and cytokine
colony stimulating factor-1, thrombopoietin, and IL11
[20,28,29].
The goal of the present study was to determine if UCBMC
could stimulate the endogenous stem/progenitor cells to
regenerate new cells. To this end, young and aged rats
were intravenously administered a single dose of UCBMC
to determine if UCBMC could increase proliferation of the
neural stem/progenitor cells as well as to determine if
there would be an effect on neurogenesis in the aged rats.
This study provides insight into how the aged stem cell
niche could be rejuvenated. Furthermore, as the UCBMC
are administered minimally invasively this study raises
the possibility of a clinically applicable therapeutic for the
aged brain.
Results
Human umbilical cord blood mononuclear cells (UCBMC) 
stimulate proliferation of the senescent hippocampal 
neural stem cell
In the first of a series of experiments we wanted to deter-
mine if UCBMC given intravenously could stimulate the
proliferation of the endogenous stem/progenitor cells in
the hippocampus. We chose to study proliferation as a
slowing of the cell cycle and a decrease in proliferation
seems to be most affected with age when compared to the
ability of the cells to survive and differentiate into neurons
which appears to occur at relatively the same rate in young
animals [30]. The effect of a single intravenous injection
of UCBMC on cell proliferation in the granule cell layer in
young (3-months old) or aged (20-months old) F344 rats
was determined by analyzing BrdU staining 24 hours after
the BrdU injections (48 hours following UCBMC injec-
tion). Using the optical fractionator method of design
based stereology [31], we found that in the aged animals
there was a significant increase (t(9) = 4.256; p < 0.005)
in the number of BrdU+ cells in the UCBMC group (2504
± 227.3 n = 5) compared to the animals that received
media alone (1549 ± 82.07 n = 6) (Figure 1A). In young
animals there was no significant effect of the UCBMC
treatment (data not shown). To determine if there might
be a prolonged effect on proliferation in the aged F344
rats BrdU injections were given 14 days after the UCBMC
treatment. Figure (1E) shows the effect of a single intrave-
nous injection of UCBMC on the number of cells that
incorporated BrdU on day 14. Stereological analysisPage 2 of 9
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significant increase in the number of BrdU+ cells (t(12) =
3.468; p < 0.01) (2357 ± 149.4 n = 6) compared to the
media-treated group (1548 ± 176.9 n = 4).
Neurogenesis is stimulated in the aged hippocampus 
following UCBMC treatment
To determine if UCBMC would also stimulate neurogene-
sis in the aged rats, doublecortin (DCX) immunostaining
was examined. Counting the number of DCX+ cells in the
SGZ/GCL, we found a significant increase (t(16) = 2.188;
p < 0.05) in the number of DCX+ cells in the aged rats 15
days after a single i.v. injection of the UCBMC (2619 ±
212.6 n = 9) compared to animals that received media
alone (1843 ± 283.9 n = 9) (Figure 2A). To confirm the
results obtained by DCX, and to determine if there was
any change in the ability of the proliferating cells to differ-
entiate following a UCBMC treatment, we injected the
animals with BrdU (50 mg/kg) for five days beginning 24
hours after our i.v. treatment. Quantifying the number of
BrdU+ cells in the SGZ/GCL using the optical fractionator
method of design based stereology we found a similar
increase in the number of BrdU+ cells in the aged UCBMC
treated group as was found using the neurogenic marker
DCX (Figure 2A–D). In aged rats, there was a significant
increase (F(2, 14) = 10.94, p < 0.005) in the number of
BrdU+ cells generated over a period of five days following
a single i.v. injection of UCBMC (2772 ± 263.3 n = 5)
compared to the rats that received media alone (1498 ±
206.1 n = 5); as determined by the Tukey's Multiple Com-
parison Test (p < 0.01). In this experiment, we also
included a group that was injected with adult human
peripheral blood mononuclear cells (PBMC) as a control
for the effect of delivering cells. The PBMC group was
determined to have significantly fewer BrdU+ cells (1712
± 171.2 n = 5) than the UCBMC treated group (p < 0.01),
but this was not significantly different from the group that
received media alone (Figure 2E–H). As with the results of
the proliferation study, young rats showed no significant
effect of UCBMC treatment (data not shown). To deter-
mine if the treatment with UCBMC might alter the pheno-
type of the newborn cells, we double labeled with the
antibodies to Tuj1, NeuN and GFAP. While exhaustive
sampling was not conducted, 50 BrdU+ cells were ana-
lyzed from each rat (4 rats per group) using confocal
microscopy for each marker and there did not appear to
be any change in phenotype due to the treatment (Figure
2I–J). To confirm that the increase in neurogenesis was
from the endogenous stem/progenitor cells, sections were
stained for HuNu to look for the presence of the trans-
planted cells in the brain. Cells positive for the HuNu
were found in the blood smears of the rats that were
treated with UCBMC, but no HuNu immunoreactive cells
were found in the hippocampus of the rats (data not
shown).
A decrease in microglia activation following UCBMC 
correlates with the increase in neurogenesis
Using the optical fractionator method of design based
stereology, we counted the number of OX-6+ cells in the
dentate gyrus 15 days after a single UCBMC injection; this
was at the same time point that we observed an increase
in DCX+ cells and BrdU+ cells. OX-6 is a marker for MHCII
and presumably stains for microglia in an activated,
Proliferation is increased in aged rats following UCBMC treatmentFigure 1
Proliferation is increased in aged rats following 
UCBMC treatment. To determine if UCBMC could stim-
ulate proliferation of the hippocampal neural progenitor/
stem cells rats received two i.p. injections of BrdU (50 mg/
kg) and were sacrifice the following day. (A) Quantification of 
the BrdU immunoreactive cell in the SGZ/GCL in aged rats 2 
days after the UCBMC treatment showed that there was a 
significant (p < 0.005) increase in the number of BrdU immu-
noreactive cells. (B, C) Photomicrographs of the dentate 
gyrus of a media-treated rat (B) and a UCBMC-treated rat 
(C) shows the BrdU staining in those animals sacrificed 2 
days after the treatment. (D)The arrow in C points to a clus-
ter of BrdU immunoreactive cells from the UCBMC-treated 
rat shown in D at higher magnification. (E) To determine 
how long proliferation might remain elevated injections of 
BrdU (50 mg/kg) began 14 days after the treatment. Quantifi-
cation of the BrdU immunoreactive cells determine that the 
UCBMC-treated group had significantly (p < 0.01) more cells 
in the SGZ/GCL then the animals that received media alone. 
(F, G) BrdU staining of the media-treated (F) and the 
UCBMC-treated (G) animals in the dentate gyrus of the hip-
pocampus 15 days after the treatment. (H) Arrow in G 
points to cells shown at higher magnification in H. (scale bar 
for B, C, F, G is 100 μm; scale bar for D, H is 25 μm)Page 3 of 9
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after the UCBMC treatment there was a significant
decrease (t(12) = 2.699; p < 0.05) in the total number of
activated OX-6+ microglia in the UCBMC group (678.7 ±
155.3 n = 7) compared to the media control (1217 ±
128.0 n = 8) (Figure 3A). The decrease in OX-6+ microglia
negatively correlated with the number of DCX+ cells
(Spearman r(15) = -- 0.6429; p < 0.01) (Figure 3E).
Morphologically the OX-6+ cells expressed two main phe-
notypes (see Figure 3F). Type 1 microglia appear to be in
a more quiescent state based on morphology Type 2
microglia were thought to represent a more activated
state. The type 1 microglia make up the majority of the
OX-6+ cells in the dentate gyrus and were found to be sig-
nificantly decreased (unpaired t(12) = 2.791; p < 0.05) in
aged rats following UCBMC treatment (426.6 ± 117.0 n =
15 days after a UCBMC treatment neurogenesis is increase in aged ratsFigure 2
15 days after a UCBMC treatment neurogenesis is increase in aged rats. To determine if UCBMC treatment could 
stimulate neurogenesis aged F344 rats were sacrificed and immunohistochemical stained for DCX and BrdU. (A) A significant 
increase (p < 0.05) in the number of DCX+ cells, quantified in the SGZ/GCL, was found in the UCBMC treated rats. (B, C) 
Photomicrographs show the dentate gyrus demonstrating the DCX immunohistochemistry in the media-treated (B) and 
UCBMC-treated (C) rats. (D) A higher magnification photomicrograph of area indicated in C shows a number of DCX+ cells 
showing the different morphologies of the cells. (E) The results obtained with DCX were confirmed by BrdU. BrdU was 
injected i.p. for five consecutive days after the single injection of UCBMC. 10 days after the last injection of BrdU the animals 
were sacrificed. Compare to both a media control as well as an human adult peripheral blood (PBMC) control the UCBMC 
treated animals had significantly more BrdU+ cells (p < 0.01). (F, G, H) Photomicorgaphs of dentate gyrus shows BrdU immuno-
histochemistry in the media-treated (F), PBMC-treated (G) and UCBMC-treated (H) rats. (I, J) Immunofluorescence was con-
ducted to determine the phenotype of the BrdU+ cells. (I) An example of the cells double labeled with BrdU+/NeuN+ (I; shown 
in orthogonal projection) and BrdU+/TUJ1+ (J; shown using maximum projection). (scale bar for B, C, F, G, H is 100 μm; scale 
bar for D is 25 μm)Page 4 of 9
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3G). The type 2 microglia, while representing a smaller
percentage of the total OX-6+ microglia, were significantly
reduced (t(12) = 3.281; p < 0.01) to a greater extent by the
UCBMC treatment (53.30 ± 13.27 n = 7) compared to
controls (212.9 ± 43.82 n = 8) than the total microglia
(Figure 3H). Fifteen days after the UCBMC treatment,
there was a 4 fold change in the number of type 2 OX-6+
microglia, whereas there was only a 1.8 fold change in the
total number of OX-6+ microglia. It appears that the
highly activated microglia are being reduced to a greater
extent by the UCBMC treatment, although all OX-6+
microglia are affected.
Discussion
The present study explored whether human umbilical
cord blood mononuclear cells (UCBMC) could improve
the neurogenic niche of the aged brain and stimulate the
endogenous stem/progenitor cells to generate new neu-
rons. As determined by stereological analysis of both DCX
and BrdU, a single peripherally administered injection of
UCBMC appeared to stimulate neurogenesis. The finding
that the administration of UCBMC also increased the
number of proliferative cells generated within 24 hours
following the treatment, suggests that the increase in neu-
rogenesis observed in this study may be a consequence of
an increase in proliferation rather than changes in differ-
entiation or survival of newly generated cells. To support
this hypothesis, it will be important to allow more time
for the cells to fully mature and then determine if there is
still no change in the phenotype of the BrdU+ cells. It will
also be important to determine what effect UCBMC have
on the survival of the BrdU+ cells.
In addition, it was determined that UCBMC were able to
increase cell proliferation for at least fifteen days in the
aged rats. This suggests that the UCBMC may have a ben-
eficial effect on the microenvironment of the aged brain.
In support of this hypothesis we show that coinciding
with an increase in neurogenesis in the aged treated rats,
there was a decrease in the number of activated microglia
in the dentate gyrus. A negative correlation between the
degree of inflammation as indicated by the activation of
microglia and the number of newborn neurons has been
previously described [32]. Consistent with previous stud-
ies showing that UCBMC have the potential to reduce
neuroinflammation [20,23,27,30] in the aged brain, we
did find that neurogenesis correlated with the number of
activated microglia, suggesting that UCBMC were stimu-
lating neurogenesis by decreasing microglia activation.
Although other possibilities cannot be excluded, since
UCBMC could be having multiple effects including
increasing trophic support as previously published
[20,28,29].
UCBMC have been shown to reduce neuroinflammation
[20,23,27,30] and, consistent with previous studies, we
show here that the peripherally administered UCBMC do
The decrease in microglia activation correlates with neuro-genesisFigur  3
The decrease in microglia activation correlates with 
neurogenesis. 15 days after the UCBMC treatment a signif-
icant reduction (p < 0.05) was found in the number of OX-6+ 
cells in the dentate gyrus of the aged rats (A). (B, C) Photom-
icrographs are shown of the hippocampus of media-treated 
(C) and UCBMC-treated (C) rats. (D) A higher magnification 
photomicrograph of area indicated by arrow in B. (E) A sig-
nificant negative correlation (p < 0.01) was found between 
the number of OX-6+ cells and the amount of neurogenesis 
as determine by the number of DCX+ cells. (F) The OX-6+ 
were further characterized based on morphology. The cell 
on the left represents a typical 'Type 1' cell the cell on the 
right represents a typical 'Type 2' cell. Both 'Type 1' (p < 
0.05; G) and 'Type 2' (p < 0.01; H) OX-6+ cells were signifi-
cantly reduced in the aged animals following UCBMC treat-
ment, but there was a greater reduction in 'Type 2' cells 
amounting to a four fold change. (scale bar for B, C is 200 
μm; scale bar for D is 25 μm)Page 5 of 9
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the factors that leads to the negative regulation of neural
stem cells is inflammation [32-34]. A primary source of
inflammation in the CNS is from the macrophages/micro-
glia which can produce a wide array of cytotoxic factors,
including proinflammatory cytokines such as tumor
necrosis factor (TNF), IL-1, IL-6 and IL-12 [35,36]. With
age, microglia shift from a quiescent state into an active
proinflammatory state. It is not clear if this change in acti-
vation state is in response to injury, infection, or debris or
if it is due to dysregulated cytokine levels. Another possi-
bility recently proposed, is that microglia becoming senes-
cent and this leads to them becoming dysfunctional
[37,38]. It has previously been demonstrated in models of
induced inflammation through the use of LPS or radia-
tion, a dramatic decrease in proliferation and neurogene-
sis occur, and when the inflammation is alleviated the
replicative potential of the stem cells returns [32,34]. This
effect is likely a protective mechanism so that the DNA is
not exposed to the noxious inflammatory environment
which could damage the replicating DNA. This correlation
also imparts support to the hypothesis that UCBMC stim-
ulate neurogenesis by decreasing inflammation, particu-
larly the activation state of microglia. However, it does not
rule out the possibility that UCBMC may be acting on
multiple targets, with microglia only representing one
part of the total mechanism.
While UCBMC do seem to have an effect on microglia, it
is not clear how this occurs. A number of studies have
shown that T-cells appear to act on macrophages/micro-
glia to cause them to adopt a phenotype that is 'pro-repair'
(i.e. the macrophages/microglia: clear debris, buffer toxic
compounds, and produce growth factors), without being
pro-inflammatory (i.e. producing TNF-α, NO, or COX-2)
and this effect can promote neurogenesis and be neuro-
protective [39-43]. As T-cells are a major fraction of
UCBMC, it is possible that the naïve T-cells in the UCBMC
are able to induce a protective T-cell mediated response in
the aged rats, since adult PBMC did not have an effect.
Alternatively, the CD34+ stem cells in the UCBMC may be
involved. Taguchi et al. [29] has shown that CD34+ stem
cells can increase both angiogenesis and neurogenesis as
part of the protective mechanism against stroke. From the
results of the current study it can not be determined if the
effects of the UCBMC are a result of direct action on the
brain or though peripheral effect. However, the fact that
we did not detect any immunoreactivity for human nuclei
in the brains of the UCBMC-treated rats raises the possi-
bility that the UCBMC may be acting through a peripheral
mechanism. Moreover, the observation that the adult
PBMC did not alter hippocampal neurogenesis ruled out
the possibility of a non-specific effect due to an influx of
cells, supporting our belief that the increase in neurogen-
esis, which occurred following treatment with UCBMC
was not due to an influx of cells but was specific to
UCBMC.
The present study did not attempt to determine if decreas-
ing senescence of the neural stem cells could reverse the
cognitive decline with age. There is still much debate sur-
rounding the role of neurogenesis in learning and mem-
ory [44-49] and whether cellular senescence of the stem
cell pool with age leads to an aging phenotype. While not
a goal of the current study, it will be important to deter-
mine if the rejuvenation of the aged stem/progenitor cell
pool can reverse the age-related cognitive decline.
In summary, this study demonstrates that a single periph-
eral injection of UCBMC could stimulate the endogenous
neural stem/progenitor cells to increase proliferation. We
also determined that the UCBMC were able to improve
the microenvironment of the aged brain by reducing the
number of activated microglia, and this reduction is cor-
related with an increase in neurogenesis. Further work will
be important to determine the mechanism of action of
UCBMC in the aged rats, including the possible role of the
immune system in a T-cell mediated response, as well as
the affects of angiogenesis via the CD34+ stem cells. It will
also be important in future experiments to determine the
duration that a single injection of UCBMC will elevated
proliferation in aged rats. Not only do the results of this
study provide novel insight into the state of the aged stem
cell niche, the ability of the UCBMC to exert their effects
while being administered minimally invasively may make
translation to the clinical setting more likely. For this rea-
son it will be important in future studies to determine the
most efficacious dose and dosing regimen. Nevertheless,
this is the first time that a systemic injection of hemat-
opoietic cells has been shown to restore the regenerative
potential of the aged brain, providing a novel insight into
how the regenerative potential of the aged stem cell niches
could be restored.
Conclusion
The results demonstrate that a single intravenous injec-
tion of UCBMC in aged rats can significantly improve the
microenvironment of the aged hippocampus and rejuve-
nate the aged neural stem/progenitor cells. Our results
raise the possibility of a peripherally administered cell
therapy as an effective approach to improve the microen-
vironment of the aged brain.
Methods
Cell preparation
Cryopreserved human umbilical cord blood mononu-
clear cells (UCBMCs) were obtained from Saneron CCEL
Therapeutics, Inc. (Tampa, FL, USA). Cryopreserved
Human peripheral blood cells (PBMC) (mononuclear
fraction) were obtained from AllCells, LLC (Emeryville,Page 6 of 9
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UCBMC or PBMC were thawed into media (Hanks' bal-
anced salt solution, HBSS, Gibco) at 37°C, washed, and
the number of viable cells was determined using the
trypan blue exclusion method [23]. Cell viability ranged
from 85 to 88%. Cell concentration was adjusted to 106
viable cells/500 μl. Rats were then anesthetized with 3%
isofluorane and randomly chosen to receive a single i.v.
injection via the penile vein of UCBMC at a dose 106 cells
shown most effective in a stroke model [22], 106 PBMC,
or media for both the aged and young rats.
Animals
All experiments were conducted in accordance with the
National Institute of Health Guide and Use of Laboratory
Animals, and were approved by the Institutional Animal
Care and Use committee of the University of South Flor-
ida, College of Medicine. Male Fisher 344 (F344) rats
(NIA contract colony, Harlan Sprague Dawley, Indianap-
olis, IN), were pair-housed in environmentally controlled
conditions (12:12 h light:dark cycle at 21 ± 1°C) and pro-
vided food and water ad lib. Two age groups of animals
young (3 months old) and aged (20 months old) were
used in this study. The mean life span of the F344 rats is
approximately 29 months with a maximal life span of 36
months [50].
Rats were then divided in three groups. Group 1 received
50 mg/kg of bromodeoxyuridine (5-bromo-2-deoxyurid-
ine, BrdU; Sigma, St. Louis, MO, USA), intraperitoneal
(i.p.) twice a day beginning 24 hours the injection of
UCBMC, and were sacrificed the subsequent day. Rats in
group 2 received BrdU (50 mg/kg, i.p.) twice a day, begin-
ning fourteen days after the administration of UCBMC
and were sacrificed on the following day. Rats in Group 3
received BrdU (50 mg/kg, i.p.) for five consecutive days,
beginning the day after the administration of UCBMC and
were the sacrificed day fifteen.
Tissue collection and processing
The rats were anesthetized with pentobarbital (50 mg/kg,
i.p.). Blood was collected by cardiac puncture and smears
were made of the blood to look for the presence of the
transplanted cells. The rats were transcardiac perfusion
with phosphate-buffered (PB), followed by 4% parafor-
maldehyde in PB. The brains were postfixed in 4% para-
formaldehyde for 12 h, after which they were transferred
into 30% sucrose in phosphate-buffered saline (PBS) for
at least 16 h, and stored at 4°C. Exhaustive sagittal sec-
tions of the left hemisphere were made, at 40 μm using a
Microm cryostat (Richard-Allan Scientific, Kalamazoo
Michigan) and stored in cryoprotectant at 4°C.
BrdU Immunohistochemistry
All immunohistochemical staining was conducted on
free-floating sections for every sixth section for the entire
hippocampus beginning with a random start and includ-
ing sections before and after the hippocampus to ensure
that the entire structure was sampled; with one exception,
in the aged animals from group 3 a one in three series was
stained to allow for sampling of an adequate number of
BrdU+ cells. For BrdU staining, sections were pretreated
with 50% formamide/2× SSC (0.3 M NaCl, 0.03 M
sodium citrate) at 65°C for 2 hours, rinsed in 2× SSC,
incubated in 2 N HCL for 30 minutes at 37°C, washed
with borate buffer (pH 8.5), then PBS. This was followed
by quenching endogenous peroxidase activity in 0.3%
H2O2 solution in 30% methanol; then one hour in block-
ing solution (0.1 M PBS supplemented with 3% normal
horse serum and 0.25% Triton X-100: PBS-TS); followed
by incubation overnight with mouse-anti-rat-BrdU
(1:100; Roche) in PBS-TS. The following day the sections
were washed and then incubated for one hour in a bioti-
nylated secondary antibody (1:200; Vector Laboratories,
Burlingame, CA) in PBS-TS; then washed before one hour
incubation in avidin-biotin substrate (ABC kit, Vector
Laboratories, Burlingame, CA); and then washed before
10 minutes incubation in DAB solution (Vector Laborato-
ries, Burlingame, CA). Sections were then mounted onto
glass slides and coverslipped with mounting medium.
Doublecortin and OX-6 Immunohistochemistry
Doublecortin (DCX) is a marker of migrating neurons
that is expressed for approximately three weeks after the
cell is born and has been shown to be a reliable indicator
of neurogenesis [51,52]. For DCX immunohistochemistry
a polyclonal goat antibody raised against human DCX
(1:200; SC-8066, Santa Cruz biotechnology, Santa Cruz,
CA, USA) was used following a similar protocol to BrdU
except the antigen retrieval steps were omitted and Goat
serum (Vector Laboratories, Burlingame, CA) was used
instead of horse serum. For OX-6 immunohistochemistry
a monoclonal antibody directed against the rat major his-
tocompatibility II (MHCII) (RT1B, Becton, Dickinson
Pharmingen, San Diego, CA, USA) was used at a concen-
tration of 1:750 in place of the other primary antibodies
all other steps were the same.
Immunofluorescence
Tissues were pretreated with 2 N HCL for 2 hours at room
temperature, washed, and incubated in blocking solution
(0.1 M PBS containing 10% goat serum and 0.3% Triton
X-100) for 1 hour at room temperature. Tissues were then
incubated in rat anti-BrdU (1:400; Accurate Chemical,
Westbury, NY) and additional primary antibodies [anti-
GFAP (1:500; Dako, Carpinteria, CA), mouse anti-NeuN
(1:100; Chemicon, Temecula, CA), mouse anti-TUJ1
(1:800; Convance, Berkeley, CA)], overnight at 4°C. Tis-Page 7 of 9
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secondary antibody conjugated to an Alexafluor probe
(Molecular Probes, Eugene, OR) was applied for 2 hour.
Following 6 washes in PBS, tissues were mounted on
slides and coverslipped using Vectashield (Vector Labs,
Burlingame, CA).
Human Nuclei immunofluorescence
To detect for the presence of the transplanted cells, blood
smears and tissue sections were stained with a mouse
monoclonal antibody that recognizes Human Nuclei anti-
gen (HuNu) (MAB 1281; 1:50; Chemicon, Temecula,
CA), and does not react with rat nuclei. Prior to incuba-
tion overnight at 4°C in the HuNu antibody, the samples
were washed in PBS and incubated in blocking solution
(0.1 M PBS containing 10% goat serum and 0.3% Triton
X-100) for 1 hour at room temperature. The HuNu anti-
body was visualized by secondary antibody conjugated to
an Alexafluor probe (Molecular Probes, Eugene, OR).
Quantification and imaging
To determine cell numbers the optical fractionator
method of unbiased stereological cell counting tech-
niques [31] was used with a Nikon Eclipse 600 micro-
scope and quantified using Stereo Investigator software
(MicroBrightField, Colchester, VT). For the proliferation
study, because of the low number of BrdU+ cell in the aged
animals the virtual grid and counting frame were both
125 μm × 125 μm in order to count all the cells that were
present in the section. For all other counts sampling was
optimized to count at least 200 cells per animal with error
coefficients less than 0.07. Outlines of the anatomical
structures were done using a 10×/0.45 objective and cell
quantification was conducted using a 60×/1.40 objective.
OX-6+ cells were counted in the entire dentate gyrus
including the subgranular zone (SGZ: defined as a two cell
diameter band on both sides of the granular cell layer
(GCL)). All other cell counts were done in the SGZ/GCL.
The phenotype of the BrdU+ cells were analyzed using an
inverted Zeiss LSM 510 confocal microscope with a 40×/
1.30 NA oil immersion objective. Argon and HeNe laser
lines in conjunction with 488 and 555 band pass filters
were applied to excite the samples using line switching to
minimize crosstalk between fluorochromes. Images and
Z-stacks were produced with dual photomultiplier detec-
tors and the LSM 5 version 3,2,0,115 software suite, and
optical Z stacks where created at 2 μm intervals through-
out the 40 μm of the sections with a guard region of 2 μm
excluded from top and bottom of the Z stack. The Z stacks
were rotated in all planes to verify double labeling.
Statistical analyses
Data are presented as mean cell number ± SEM. Statistical
analysis was performed using an unpaired, two-side t-test,
or a one-way ANOVA followed by a Tukeys post-hoc test. p
< 0.05 was considered to be significant.
Abbreviations
GCL (granular cell layer), PBMC (peripheral blood mono-
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